Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - July 2011

The National Institute of Health and Clinical Excellence (NICE) has published new guidance for the month of July 2011. This month there are two technology appraisals that impact upon primary care.

Retigabine (Trobalt®) is recommended (QRG) for the adjuvant treatment of partial onset seizures in epilepsy. NICE has recommended that this treatment as an option for individuals aged 18 years and older in whom existing treatments have proven ineffective or have been poorly tolerated. Treatment changes would normally be recommended by a specialist.

Agomelatine (Valdoxan®) has not been recommended (QRG) for the treatment of major depressive episodes. The appraisal was terminated when the manufacturer advised that they would not be making an evidence submission as the current evidence would not allow an economic case to be made. NICE has noted that NHS organisations should take into consideration the reasons why an evidence submission was not made when deciding whether or not to recommend local use of agomelatine.

Action: Clinicians should be aware of these recommendations and implement any necessary changes to practice.

Share 'NICE Guidance - July 2011' on Email Share 'NICE Guidance - July 2011' on Delicious Share 'NICE Guidance - July 2011' on Digg Share 'NICE Guidance - July 2011' on Facebook Share 'NICE Guidance - July 2011' on Google+ Share 'NICE Guidance - July 2011' on reddit Share 'NICE Guidance - July 2011' on StumbleUpon Share 'NICE Guidance - July 2011' on Twitter

atomic-wealth

No Comments to “NICE Guidance - July 2011”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,318 spam comments.

atomic-wealth
fond-illness
summer